57 related articles for article (PubMed ID: 17207548)
21. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
[TBL] [Abstract][Full Text] [Related]
22. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
Dittmann KH; Mayer C; Ohneseit PA; Raju U; Andratschke NH; Milas L; Rodemann HP
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):203-12. PubMed ID: 17996386
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Anai S; Tanaka M; Shiverick KT; Kim W; Takada S; Boehlein S; Goodison S; Mizokami A; Rosser CJ
J Urol; 2007 May; 177(5):1913-7. PubMed ID: 17437847
[TBL] [Abstract][Full Text] [Related]
24. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Grösch S; Maier TJ; Schiffmann S; Geisslinger G
J Natl Cancer Inst; 2006 Jun; 98(11):736-47. PubMed ID: 16757698
[TBL] [Abstract][Full Text] [Related]
28. Targeting apoptosis pathways by Celecoxib in cancer.
Jendrossek V
Cancer Lett; 2013 May; 332(2):313-24. PubMed ID: 21345578
[TBL] [Abstract][Full Text] [Related]
29. Role of COX-2 selective inhibitors for prevention and treatment of cancer.
Amir M; Agarwal HK
Pharmazie; 2005 Aug; 60(8):563-70. PubMed ID: 16124396
[TBL] [Abstract][Full Text] [Related]
30. Compositions for treatment of cancer and inflammation.
Lev-Ari S; Lichtenberg D; Arber N
Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):55-62. PubMed ID: 18289124
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.
Mao JT; Cui X; Reckamp K; Liu M; Krysan K; Dalwadi H; Sharma S; Hazra S; Strieter R; Gardner B; Dubinett SM
Clin Lung Cancer; 2005 Jul; 7(1):30-9. PubMed ID: 16098242
[TBL] [Abstract][Full Text] [Related]
32. Cyclooxygenase-2: a therapeutic target for prostate cancer.
Pruthi RS; Wallen EM
Clin Genitourin Cancer; 2005 Dec; 4(3):203-11. PubMed ID: 16425990
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway.
Moreno J; Krishnan AV; Peehl DM; Feldman D
Anticancer Res; 2006; 26(4A):2525-30. PubMed ID: 16886660
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
